Supporting Information

The unique opportunity of glass wastes utilization as resources for catalytic applications: Toward a cleaner environment

Somayeh Zolfagharinia, Nadiya Koukabi and Eskandar Kolvari *

Department of Chemistry, Semnan University, Semnan, Iran. E-mail: kolvari@semnan.ac.ir; Fax: +98-23-336-54110; Tel: +98-23-336-54058

Table of Contents

-Spectral data of Ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry1), (Page 4).

- Fig. 1. FT-IR spectrum of Ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry1), (Page 5).

- Fig. 2. 1H-NMR spectrum of Ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry1), (Page 6).

- Fig. 3. 13C-NMR spectrum of Ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry1), (Page 7).

-Spectral data of ethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 2), (Page 8).

- Fig. 4. FT-IR spectrum of ethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 2), (Page 9).

- Fig. 5. 1H-NMR spectrum of ethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 2), (Page 10).

- Fig. 6. 13C-NMR spectrum of ethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 2), (Page 11).

-Spectral data of ethyl 4-(2-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 3), (Page 12)

Fig. 7. FT-IR spectrum of ethyl 4-(2-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 3), (Page 13).

- Fig. 8. 1H-NMR spectrum of ethyl 4-(2-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 3), (Page 14).

- Fig. 9. 13C-NMR spectrum of ethyl 4-(2-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 3), (Page 15).
-Spectral data of ethyl 6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 11), (Page 16).

Fig. 10. FT-IR spectrum of ethyl 6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 11), (Page 17).

-Fig. 11. $^1$H-NMR spectrum of ethyl 6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 11), (Page 18).

-Fig. 12. $^{13}$C-NMR spectrum of ethyl 6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 11), (Page 19).

-Spectral data of ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (table 3, entry 6), (Page 20).

Fig. 13. FT-IR spectrum of ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (table 3, entry 6), (Page 21).

-Fig. 14. $^1$H-NMR spectrum of ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (table 3, entry 6), (Page 22).

-Fig. 15. $^{13}$C-NMR spectrum of ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (table 3, entry 6), (Page 23).

-Spectral data of ethyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 12), (Page 24).

Fig. 16. FT-IR spectrum of ethyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 12), (Page 25).

-Fig. 17. $^1$H-NMR spectrum of ethyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 12), (Page 26).

-Fig. 18. $^{13}$C-NMR spectrum of ethyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 12), (Page 27).

-Spectral data of ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 13), (Page 28).

Fig. 19. FT-IR spectrum of ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 13), (Page 29).

-Fig. 20. $^1$H-NMR spectrum of ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 13), (Page 30).

-Fig. 21. $^{13}$C-NMR spectrum of ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 13), (Page 31).
Spectral data of methyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 19), (Page 32).

Fig.22. FT-IR of methyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 19), (Page 33).

- Fig. 23. $^1$H-NMR spectrum of methyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 19), (Page 34).

- Fig. 24. $^{13}$C-NMR spectrum of methyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 19), (Page 35).

Spectral data of 3,3,6,6-tetramethyl-9-(4-nitrophenyl)-3,4,5,6,7,9-hexahydro-$^1$H-xanthene-1,8(2$^H$)-dione (Table 5, entry 6), (Page 36).

Fig.25. FT-IR spectrum of 3,3,6,6-tetramethyl-9-(4-nitrophenyl)-3,4,5,6,7,9-hexahydro-$^1$H-xanthene-1,8(2$^H$)-dione (Table 5, entry 6), (Page 37).

- Fig. 26. $^1$H-NMR spectrum of 3,3,6,6-tetramethyl-9-(4-nitrophenyl)-3,4,5,6,7,9-hexahydro-$^1$H-xanthene-1,8(2$^H$)-dione (Table 5, entry 6), (Page 38).

- Fig. 27. FT-IR spectrum of 3,3,6,6-tetramethyl-9-(p-tolyl)-3,4,5,6,7,9-hexahydro-$^1$H-xanthene-1,8(2$^H$)-dione (Table 5, entry 14), (Page 39).

- Fig. 28. $^1$H-NMR spectrum of 3,3,6,6-tetramethyl-9-(p-tolyl)-3,4,5,6,7,9-hexahydro-$^1$H-xanthene-1,8(2$^H$)-dione (Table 5, entry 14), (Page 40).

- Spectral data of 9-(4-bromophenyl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-$^1$H-xanthene-1,8(2$^H$)-dione (Table 5, entry 8), (Page 42).

Fig.29. FT-IR of 9-(4-bromophenyl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-$^1$H-xanthene-1,8(2$^H$)-dione (Table 5, entry 8), (Page 43).

- Fig. 30. $^1$H-NMR of 9-(4-bromophenyl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-$^1$H-xanthene-1,8(2$^H$)-dione (Table 5, entry 8), (Page 44).

Spectral data of some selected compounds from table3.
Ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry1).

Melting point: 207-208, FT-IR (KBr), ν.max (cm⁻¹): 3247.90, 3116.75, 2977.89, 1720.39, 1643.24, 1465.80, 1226.64, 1095.49, 779.19, 702.0. ¹H-NMR (300 MHz; CDCl₃): δ_H (ppm)= 8.62 (s, 1H, NH), 7.24-7.31 (m, 5H, ArH), 6.1 (s, 1H, NH), 5.38 (s, 1H, CH), 4.03 (q, 2H, OCH₂), 2.32 (s, 3H, CH₃), 1.13 (t, 3H, OCH₂CH₃). ¹³C NMR (75 MHz; CDCl₃): δ_C (ppm): 14.12, 18.55, 55.59, 59.97, 101.23, 126.56, 127.88, 128.66, 143.73, 146.48, 153.73, 165.65.
Fig. 1. FT-IR (KBr discs) spectrum of ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry1).
Fig. 2. $^1$H-NMR spectrum of ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry1).
Fig. 3. $^{13}$C-NMR spectrum of ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry1).
Ethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 2).

Melting point: 215-216. FT-IR (KBr), \( \nu_{\text{max}} \) (cm\(^{-1}\)): 3240.19, 3116.75, 2977.89, 1704.96, 1650.95, 1419.51, 1226.64, 1091.63, 779.19. \(^1\)H-NMR (300 MHz; CDCl\(_3\)): \( \delta_H \) (ppm): 8.44 (s, 1H, NH), 7.22-7.29 (m, 4H, ArH), 6.1 (s, 1H, NH), 5.36 (s, 1 H, CH), 4.04 (q, 2 H, OCH\(_2\)), 2.32 (s, 3 H, CH\(_3\)) , 1.15 (t, 3H, OCH\(_2\)CH\(_3\)). \(^{13}\)C-NMR (75 MHz; CDCl\(_3\)): \( \delta_C \) (ppm): 14.15, 18.63, 55.02, 60.14, 101.02, 127.99, 128.84, 133.69, 142.19, 146.54, 153.48, 165.45.
Fig. 4. FT-IR (KBr discs) spectrum of ethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 2).
Fig. 5. $^1$H-NMR spectrum of ethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry2).
Fig. 6. $^{13}$C-NMR spectrum of ethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry2).
Ethyl 4-(2-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 3).

Melting point: 214-216. FT-IR (KBr), v. max (cm⁻¹): 3234.40, 3110.97, 2977.89, 1701.10, 1645.17, 1454.23, 1222.79, 1081.99, 761.83. ¹H-NMR (CDCl₃, 300 MHz): δH (ppm): 9.08 (s, 1 H, NH), 7.19-7.37 (m, 4 H, ArH), 5.98 (s, 1 H, NH), 5.86 (s, 1H, CH), 3.97 (q, 2 H, OCH₂), 2.41 (s, 3 H, CH₃), 1.02(t, 3H, OCH₂CH₃). ¹³C-NMR (75 MHz; CDCl₃) δC (ppm): 13.97, 18.23, 52.06, 59.93, 98.8, 127.51, 128.03, 129.23, 129.75, 132.55, 139.58, 148.56, 153.42, 165.33.
Fig. 7. FT-IR (KBr discs) spectrum of ethyl 4-(2-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 3).
Fig. 8. $^1$H-NMR spectrum of ethyl 4-(2-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry 3).
Fig. 9. $^{13}$C-NMR spectrum of ethyl 4-(2-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry 3).
Ethyl 6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 11).

![Chemical structure](image)

Melting point: 203-204. FT-IR (KBr), v. max (cm⁻¹): 3245.97, 3114.82, 2979.82, 1724.24, 1649.02, 1460.01, 1222.79, 1089.71, 786.90. ¹H-NMR (CDCl₃, 300 MHz) δ_H (ppm): 8.75 (s, 1 H, NH), 7.09-7.21 (m, 4 H, ArH), 6.22 (s, 1 H, NH), 5.34 (s, 1 H, CH), 4.04 (q, 2 H, OCH₂), 2.3 (s, 3 H, CH₃), 1.15 (t, 3H, OCH₂CH₃). ¹³C-NMR (75 MHz; CDCl₃) δ_C (ppm): 14.16, 18.50, 21.09, 55.18, 59.93, 101.35, 126.45, 129.30, 137.52, 140.91, 146.41, 153.99, 165.74.
Fig.10. FT-IR (KBr discs) spectrum of ethyl 6-methyl-2-oxo-4-((p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table3, entry 11).
Fig. 11. $^1$H-NMR spectrum of ethyl 6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry 11).
Fig. 12. $^{13}$C-NMR spectrum of ethyl 6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry 11).
Ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5 carboxylate (table 3, entry 6).

Melting point: 209-211. FT-IR (KBr), ν. max (cm⁻¹): 3247.90, 3116.75, 2977.89, 1720.39, 1643.24, 1519.80, 1348.15, 1218, 1097.42, 856.34, 779.19. ¹H-NMR (CDCl₃, 300 MHz) δH (ppm): 7.94 (s, 1H, NH), 5.91 (s, 1H, NH), 8.18 (d, 2H, Ar-H), 7.5 (d, 2H, Ar-H), 5.52 (s, 1H, CH), 4.07 (q, 2H,CH₂O), 2.37 (s, 3H, CH₃), 1.17 (t, 3H,OCH₂-CH₃). ¹³C-NMR (75 MHz; CDCl₃) δC (ppm): 14.18, 18.94, 55.18, 60.43, 100.56, 124.1, 127.57, 147.56, 148.03, 149.71, 150.34, 165.15.
Fig. 13. FT-IR (KBr discs) spectrum of ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5 carboxylate in CDCl$_3$ (table 3, entry 6).
Fig.14. $^1$H-NMR spectrum of ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5 carboxylate in CDCl$_3$ (table 3, entry 6).
Fig. 15. $^{13}$C-NMR spectrum of ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5 carboxylate in CDCl$_3$ (table 3, entry 6).
Ethyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 12).

Melting point: 232-234. FT-IR (KBr), ν. max (cm\(^{-1}\)): 3417, 3263.33, 2985.60, 1704.96, 1650.95, 1515.94, 1226.61, 1095.49, 786.90.

\(^1\)H-NMR (CDCl\(_3\), 300 MHz) δ\(_H\) (ppm): 6.79 (m, 3 H, ArH), 5.31 (S, 1 H, CH), 4.03 (q, 2 H, OCH\(_2\)), 2.33(s, 3 H, CH\(_3\)), 1.39(t, 3 H, OCH\(_2\)CH\(_3\)), 1.15(t, 3H, OCH\(_2\)CH\(_3\)). \(^1\)C-NMR (75 MHz; CDCl\(_3\)) δ\(_C\) (ppm): 14.13, 14.77, 17.74, 53.55, 59.15, 63.93, 99.64, 112.3, 115.38, 118.45, 135.9, 146.13, 146.32, 147.84, 152.31, 165.47.
Fig. 16. FT-IR (KBr discs) spectrum of ethyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 12).
Fig. 17. $^1$H-NMR spectrum of ethyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry 12).
Fig. 18. $^{13}$C-NMR spectrum of ethyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry 12).
Ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 13).

Melting point: 175-177. FT-IR (KBr), v. max (cm$^{-1}$): 3247.90, 3116.75, 2940.34, 1712.67, 1650.95, 1519.80, 1234.36, 1095.49, 786.90. $^1$H-NMR (CDCl$_3$, 300 MHz) $\delta_H$ (ppm): 9.15 (s, 1 H, NH), 7.68 (s, 1 H, NH), 5.09 (s, 1 H, CH), 6.70-6.89 (m, 3H, ArH), 3.95 (q, 2 H, OCH$_2$CH$_3$), 3.37 (s, 3 H, CH$_3$), 3.95 (q, 2 H, OCH$_2$CH$_3$), 2.24 (s, 3 H, CH$_3$). $^{13}$C-NMR (75 MHz; CDCl$_3$) $\delta_C$ (ppm): 14.15, 17.76, 53.49, 55.4, 55.52, 59.19, 99.39, 110.45, 111.72, 117.9, 137.35, 148.06, 148.15, 148.48, 152.29, 165.43.
Fig. 19. FT-IR (KBr discs) spectrum of ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 13).
Fig. 20. $^1$H-NMR spectrum of ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry 13).
Fig. 21. $^{13}$C-NMR spectrum of ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-4H-pyrimidine-5-carboxylate in CDCl$_3$ (Table 3, entry 13).
Methyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 19).

![Chemical structure](image)

Melting point: 254-256. FT-IR (KBr), v. max (cm\(^{-1}\)): 3317.34, 3249.76, 2989.34, 1704.96, 1685.67, 1438.80, 1238.2, 1095.49, 759.90. \(^1\)H-NMR (DMSO, 300 MHz) \(\delta_h\) (ppm): 9.12 (S, 1 H, NH), 8.79 (S, 1 H, NH), 7.61 (S, 1 H, OH), 6.57-6.77 (m, 3 H, ArH), 5.02 (S, 1 H, CH), 5.92 (q, 2H, OCH\(_2\)), 3.51 (S, 3H, OCH\(_3\)), 2.22 (S, 3H, CH\(_3\)), 1.27 (t, 3H, CH\(_3\)). \(^{13}\)C-NMR (75 MHz; DMSO) \(\delta_c\) (ppm): 14.76, 17.78, 50.75, 53.42, 63.92, 99.34, 112.26, 115.39, 118.33, 135.7, 146.15, 146.37, 148.15, 152.29, 165.95.
Fig. 22. FT-IR (KBr discs) spectrum of methyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (Table 3, entry 19).
Fig. 23. $^1$H-NMR spectrum of methyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in DMSO (Table 3, entry 19).
Fig. 24. $^{13}$C-NMR spectrum of methyl 4-(3-ethoxy-4-hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate in DMSO (Table 3, entry 19).
Spectruml data of some selected compounds from table 5.

3,3,6,6-tetramethyl-9-(4-nitrophenyl)-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione (Table 5, entry 6).

Melting point: 226-228. FT-IR (KBr), ν. max (cm\(^{-1}\)): 2958.60, 1662.52, 1514.02, 1361.65, 1201.57. \(^1\)H-NMR (DMSO, 300 MHz) \(\delta_H\) (ppm): 0.99 (S, 6 H), 1.12 (S, 6 H), 2.14-2.27 (q, 4 H), 2.49 (S, 4 H), 4.82 (S, 1H), 7.46-7.48 (d, 2H), 8.08-8.11 (d, 2H).
Fig. 25. FT-IR (KBr discs) spectrum of 3,3,6,6-tetramethyl-9-(4-nitrophenyl)-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione (Table 5, entry 6).
Fig. 26. $^1$H-NMR spectrum of 3,3,6,6-tetramethyl-9-(4-nitrophenyl)-3,4,5,6,7,9-hexahydro-$1H$-xanthene-1,8($2H$)-dione in DMSO (Table 5, entry 6).
3,3,6,6-tetramethyl-9-(p-tolyl)-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione (Table 5, entry 14).

![Chemical structure](attachment:image.png)

Melting point: 215-217. FT-IR (KBr), v. max (cm$^{-1}$): 2958.60, 1664.45, 1357.79, 1232.42, 1164.92, 999.057, 840.90. $^1$H-NMR (DMSO, 300 MHz) $\delta_H$ (ppm): 0.99 (S, 6 H), 1.095 (S, 6 H), 2.13-2.23(q, 4 H), 2.41 (S, 3H), 2.45 (S, 4H), 4.70 (S, 1H), 7.005-7.025 (d, 2H), 7.16-7.18 (d, 2H).
Fig. 27. FT-IR (KBr discs) spectrum of 3,3,6,6-tetramethyl-9-(p-tolyl)-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione (Table 5, entry 14).
Fig. 28. $^1$H-NMR spectrum of 3,3,6,6-tetramethyl-9-(p-tolyl)-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione in DMSO (Table 5, entry 14).
9-(4-bromophenyl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione (Table 5, entry 8).

Melting point: 239-241. FT-IR (KBr), \( \nu \) max (cm\(^{-1}\)): 2950.88, 1660.59, 1361.65, 1191.97, 1008.70, 852.47. \(^1\)H-NMR (DMSO, 300 MHz) \( \delta \) (ppm): 0.98 (S, 6 H), 1.10 (S, 6 H), 2.14-2.25 (q, 4 H), 2.46 (S, 4 H), 4.69 (S, 1H), 7.16-7.18 (d, 2H), 7.32-7.34 (d, 2H).
Fig. 29. FT-IR (KBr discs) spectrum of 9-(4-bromophenyl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione (Table 5, entry 8).
Fig. 30. $^1$H-NMR spectrum of 9-(4-bromophenyl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1$H$-xanthene-1,8(2$H$)-dione in DMSO (Table 5, entry 8).